Insulin is made two ways: naturally by your pancreas and commercially through genetically engineered microorganisms. In your body, specialized cells produce insulin from a larger precursor protein that gets trimmed down to its active form. In pharmaceutical manufacturing, bacteria or yeast are programmed with the human insulin gene, grown in large fermentation tanks, and the insulin they produce is purified through multiple steps before reaching a pharmacy shelf.
How Your Body Makes Insulin
Insulin production starts in the beta cells of your pancreas, clustered in tiny groups called islets of Langerhans. These cells read the insulin gene and first build a longer, inactive protein called proinsulin. Think of proinsulin as insulin with an extra middle section (called the C-peptide) holding two chains together like a temporary bridge.
To activate it, your cells use a precise two-step cutting process. First, one enzyme clips the connection between the insulin’s B chain and the C-peptide. Then a second enzyme cuts the other end, removing the C-peptide entirely. A third enzyme cleans up any leftover amino acid residues at the cut sites. What remains is the mature insulin molecule: two short protein chains (A and B) linked by chemical bonds. The finished insulin is packaged into tiny storage compartments inside the beta cell, ready to be released into the bloodstream when your blood sugar rises.
From Animal Pancreases to Genetic Engineering
Before the 1980s, all medical insulin came from animals. In the 1920s, Frederick Banting and his assistant Charles Best discovered they could extract a blood-sugar-lowering substance from dog pancreases. They quickly moved to using whole beef pancreases, and the biochemist J.B. Collip figured out how to purify the extract enough for human use. For the next six decades, pharmaceutical companies processed enormous quantities of cow and pig pancreases to meet global insulin demand.
This animal-sourced insulin worked, but it wasn’t identical to human insulin. Some patients developed immune reactions, building up antibodies that made the insulin less effective over time. Improvements in purification technology during the 1970s helped reduce these reactions, but the real breakthrough came from recombinant DNA technology, which made it possible to produce insulin that is chemically identical to the human version.
How Recombinant Insulin Is Made
The process starts in the lab, where scientists build a synthetic copy of the human insulin gene. This gene is inserted into a small ring of DNA called a plasmid, which acts as a delivery vehicle. The plasmid is then placed inside a host microorganism, usually the bacterium E. coli or a type of yeast. Once the microorganism takes up the plasmid, it reads the human gene and begins producing insulin (or a precursor to insulin) alongside its own proteins.
These engineered microorganisms are grown in large fermentation tanks under carefully controlled conditions, including specific temperatures, pH levels, and nutrient mixtures. A typical production run uses bioreactors holding 15 to 30 liters or more of growth media, with precise concentrations of minerals, sugars, and other nutrients to maximize yield. The microorganisms multiply rapidly and churn out insulin precursor protein as they grow.
Bacteria vs. Yeast as Production Hosts
E. coli bacteria grow fast, are cheap to maintain, and produce high quantities of protein. The tradeoff is that they store the insulin precursor inside the cell as clumped, misfolded masses called inclusion bodies. Extracting usable insulin from these clumps requires dissolving them and then chemically coaxing the protein to fold into the correct shape, a process that adds complexity.
Yeast cells, by contrast, can fold proteins correctly on their own and secrete the insulin precursor directly into the surrounding liquid, which simplifies collection. Yeast also performs chemical modifications to proteins that bacteria cannot. However, yeast produces insulin at a much lower rate per cell. In practice, the overall output of both systems ends up comparable when scaled to industrial-sized bioreactors, so manufacturers choose based on their preferred purification workflow.
Purification and Quality Control
Raw insulin harvested from fermentation tanks is far from ready for injection. It contains bacterial or yeast debris, other proteins, and partially formed insulin molecules that all need to be removed. Purification typically involves multiple rounds of chromatography, a technique that separates molecules based on their size, charge, or chemical properties. Manufacturers commonly use cation exchange chromatography (which sorts proteins by electrical charge) followed by reverse-phase high-performance liquid chromatography, which provides an extremely fine level of separation.
The purity standards are strict. Under United States Pharmacopeia requirements, purified insulin must have a potency of at least 27.0 units per milligram. No more than 1% of the final product can be high-molecular-weight protein contaminants. Proinsulin contamination is capped at 10 nanograms per milligram, and degraded forms of insulin cannot exceed 10% of the total. For insulin derived from a single species source, cross-contamination from other species must stay below 1%. These tight limits ensure that what ends up in a vial is almost entirely active, correctly structured human insulin.
What Goes Into an Insulin Vial Besides Insulin
The insulin molecule on its own is fragile. It can clump together, break down, or lose potency if not properly stabilized. Commercial insulin formulations include several additives to prevent this. Zinc is added because insulin naturally forms stable six-molecule clusters (hexamers) around zinc ions, the same way your beta cells store it. These hexamers protect the insulin from degradation and extend shelf life.
A preservative called metacresol serves double duty: it kills microbes that could contaminate a multi-use vial, and it helps stabilize the hexamer structure through chemical bonding. Glycerol is included as a tonicity agent, ensuring the solution matches the salt concentration of your body so injections don’t sting or damage tissue. Some newer formulations use alternative preservatives like phenoxyethanol, which actually breaks apart the hexamers and keeps insulin in its single-molecule form, allowing faster absorption after injection.
How Insulin Analogs Are Designed
Standard recombinant human insulin works well, but it doesn’t perfectly mimic the body’s natural insulin release patterns. To solve this, manufacturers tweak the amino acid sequence slightly to change how fast or slow the insulin acts.
For rapid-acting insulin, the changes are small but impactful. Insulin lispro swaps the positions of two amino acids near the end of the B chain (switching a proline and a lysine). Insulin aspart replaces one proline with an aspartate at the same region. Both modifications prevent insulin molecules from clumping into hexamers as tightly, so they break apart and absorb into the bloodstream faster after injection.
Long-acting insulin takes the opposite approach. Insulin glargine replaces one amino acid on the A chain and adds two arginine residues to the end of the B chain. These changes shift the protein’s chemistry so it forms tiny crystals under the skin that dissolve slowly, providing a steady baseline of insulin over 24 hours. All of these analogs are manufactured using the same recombinant DNA and fermentation process as standard human insulin, just with a slightly different gene sequence programmed into the microorganisms at the start.